AbbVie exercises licensing option for a drug from Harpoon collaboration

AbbVie and Harpoon Therapeutics have announced that the former will has licensed the B cell maturation antigen (BCMA)-targeting drug HPN217 for multiple myeloma from the pair’s drug discovery collaboration. AbbVie and Harpoon entered into a drug discovery collaboration in October 2017 to leverage the latter’s Tri-specific T cell Activating Construct (TriTAC) technology to discover T cell-focused immuno-oncology drugs. Financial terms of this collaboration were not publicly disclosed by either company. AbbVie’s decision to exercise the option and licensing of HPN217 represents a payment of up to $510m in upfront, option and milestone payments to Harpoon; $50m could be paid by AbbVie once the first patient is treated with HPN217 in a clinical trial. Harpoon Therapeutics chief medical officer Natalie Sacks commented: “As our pipeline of initial TriTAC clinical candidates advance in prostate and ovarian cancers, we are thrilled to partner with AbbVie in pursuit of therapies geared towards haematologic cancers.

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Spotlight

Resources